Article Text

Download PDFPDF
Faecal shedding of parvovirus deoxyribonucleic acid following modified live feline panleucopenia virus vaccination in healthy cats
  1. Michèle Bergmann1,
  2. Stephanie Schwertler1,
  3. Stephanie Speck2,
  4. Uwe Truyen2,
  5. Sven Reese3 and
  6. Katrin Hartmann1
  1. 1 Clinic of Small Animal Medicine, LMU Munich, Munich, Germany
  2. 2 Institute for Animal Hygiene and Veterinary Public Health, University of Leipzig, Leipzig, Germany
  3. 3 Department of Veterinary Sciences, Institute for Anatomy, Histology and Embryology, LMU Munich, Munich, Germany
  1. E-mail for correspondence; n.bergmann{at}medizinische-kleintierklinik.de

Abstract

Positive canine parvovirus (CPV) faecal test results have been reported in dogs after modified live virus (MLV) vaccination. Thus, the aim was to investigate feline panleucopenia virus (FPV) shedding in recently vaccinated, adult, clinically healthy cats and to assess related factors. Forty cats were vaccinated with an FPV MLV vaccine. Faeces of cats were tested for presence of parvovirus DNA on days 7, 14, 21 and 28 by quantitative real-time PCR; DNA-positive samples were subjected to partial VP2 gene sequencing. Virus isolation was performed whenever sufficient amounts of faeces were available. Serum antibody titres were measured by haemagglutination inhibition on days 0, 7 and 28. Overall, 30.0 per cent (12/40; 95% CI 18.0 to 45.6) of cats shed parvovirus DNA. Sequencing revealed FPV vaccine virus DNA in three cats, FPV field virus DNA in four cats and CPV field virus DNA in one cat. Shedding was significantly associated with lack of prevaccination antibody titres (40) (P=0.016; OR: 6.44; 95% CI 1.44 to 28.89) and with postvaccination titre increases (fourfold) (P=0.029; OR: 5.00; 95% CI 1.17 to 21.39). Shedding of field or vaccine virus DNA seems to be common in healthy cats which can be a concern in shelters and catteries. Diagnostic tools should be developed to facilitate differentiation of vaccine and field virus shedding.

  • FPV
  • faeces
  • MLV
  • real-time PCR
  • vaccine
View Full Text

Statistics from Altmetric.com

Footnotes

  • Funding This study was funded by Merial, Lyon, France.

  • Disclaimer Merial played no role in the collection and interpretation of data, or in the decision to submit the manuscript for publication. There is no commercial conflict of interest as the information generated here is solely for scientific dissemination.

  • Competing interests None declared.

  • Ethics approval The protocol was approved by the responsible authorities of the Government of Upper Bavaria (reference number 55.2-1-54-2532.3-62-11).

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Presented at Parts of the results were presented as an abstract (<250 words) and oral presentation at the ACVIM Congress in Washington, 2017.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.